Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2311 to 2325 of 9039 results

  1. Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]

    Awaiting development Reference number: GID-TA11840 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Electrocautery cutting balloon treatment for pelviureteric junction obstruction

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Giredestrant for adjuvant treatment of oestrogen-receptor positive HER2-negative early breast cancer [GID-TA12031

    Awaiting development Reference number: GID-TA12031 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    In development Reference number: GID-TA11565 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  5. Upadacitinib for treating giant cell arteritis [ID6299]

    In development Reference number: GID-TA11330 Expected publication date:  14 October 2026

    Technology appraisal guidance
    In development

  6. Budesonide orodispersible tablet for maintaining remission of eosinophilic oesophagitis in people 18 years and over [ID6486]

    Awaiting development Reference number: GID-TA11623 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]

    Awaiting development Reference number: GID-TA11198 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pelabresib with ruxolitinib for treating myelofibrosis [TSID12391]

    Awaiting development Reference number: GID-TA12017 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Depemokimab for treating eosinophilic granulomatosis with polyangiitis [TSID12383]

    Awaiting development Reference number: GID-TA12007 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]

    In development Reference number: GID-TA11625 Expected publication date:  16 December 2026

    Technology appraisal guidance
    In development

  11. Treprostinil diethanolamine for treating pulmonary arterial hypertension [ID6366]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]

    Awaiting development Reference number: GID-TA10967 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]

    Awaiting development Reference number: GID-TA11874 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Nipocalimab for treating generalised myasthenia gravis [ID6562]

    Awaiting development Reference number: GID-TA11492 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Isavuconazol for treating invasive aspergillosis or mucormycosis in people 1 to 17 years [TSID12284]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation